KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Common Equity: 2019-2024

Historic Common Equity for Ginkgo Bioworks Holdings (DNA) over the last 6 years, with Dec 2024 value amounting to $716.1 million.

  • Ginkgo Bioworks Holdings' Common Equity fell 29.85% to $559.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $559.8 million, marking a year-over-year decrease of 29.85%. This contributed to the annual value of $716.1 million for FY2024, which is 34.73% down from last year.
  • According to the latest figures from FY2024, Ginkgo Bioworks Holdings' Common Equity is $716.1 million, which was down 34.73% from $1.1 billion recorded in FY2023.
  • Over the past 5 years, Ginkgo Bioworks Holdings' Common Equity peaked at $1.7 billion during FY2022, and registered a low of $470.1 million during FY2020.
  • For the 3-year period, Ginkgo Bioworks Holdings' Common Equity averaged around $1.2 billion, with its median value being $1.1 billion (2023).
  • In the last 5 years, Ginkgo Bioworks Holdings' Common Equity soared by 233.45% in 2021 and then tumbled by 36.81% in 2023.
  • Ginkgo Bioworks Holdings' Common Equity (Yearly) stood at $470.1 million in 2020, then surged by 233.45% to $1.6 billion in 2021, then grew by 10.78% to $1.7 billion in 2022, then slumped by 36.81% to $1.1 billion in 2023, then slumped by 34.73% to $716.1 million in 2024.